Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 5/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 13/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19075591 | 0.84 | CNR2 (0.38) | SSTR4MAPK1CNR2CNR1 | |
| SCHEMBL17247992 | 0.80 | MAPK1 (0.43) | SSTR4MAPK1CFTR | |
| SCHEMBL15599341 | 0.77 | SCN9A (0.44) | SSTR4MAPK1CFTR | |
| SCHEMBL17248007 | 0.77 | SSTR4 (0.46) | SSTR4MAPK1CFTR | |
| SCHEMBL19083788 | 0.76 | SSTR4 (0.45) | SSTR4CNR2 | |
| SCHEMBL21748968 | 0.75 | SSTR4 (0.64) | SSTR4 | |
| SCHEMBL21748748 | 0.73 | SSTR4 (0.65) | SSTR4CNR2 | |
| SCHEMBL12093551 | 0.73 | SSTR4 (0.43) | SSTR4 | |
| SCHEMBL17244884 | 0.70 | MAPK1 (0.41) | SSTR4MAPK1CFTR | |
| SCHEMBL28027840 | 0.69 | CNR2 (0.43) | SSTR4CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SSTR4 1035/4885MAPK1 4290/4885CNR2 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.